Compare M&T Bank Corporation (MTB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Revvity Inc — how do they compare? M&T Bank Corporation trades at $217.49 (market cap $31.42B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and Revvity Inc for 12 Days on average.
| MTB | RVTY | |
|---|---|---|
Market Cap | $31.42B | $16.98B |
Volume | 1,438,219 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $254.09 | $157.36 |
52-Week Low | $178.63 | $82.26 |
Typical Hold Time | 100 Days | 12 Days |
Enterprise Value | $47.77B | $19.30B |
Dividend Yield | 2.76% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTB trades at $217.49, up 0.41% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 11.52, net income margin of 30.85%, and three consecutive quarterly EPS beats. Recent news highlights loan growth, AI investments, and a new branch opening, while the company maintains a consistent dividend.
The outlook is mixed; analyst consensus is a Buy with a $258.92 price target, but technicals suggest near-term pressure. Key opportunities include earnings momentum and dividend stability, while risks involve cash flow volatility and high debt levels. The stock offers value but requires monitoring of upcoming Q3 2026 earnings.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
